2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)
  5. Polo-like Kinase (PLK) Isoform
  6. Polo-like Kinase (PLK) Inhibitor

Polo-like Kinase (PLK) Inhibitor

Polo-like Kinase (PLK) Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-RS10713
    Plk1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS10722
    Plk4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-164955
    TTK/PLK1-IN-1
    		Inhibitor
    TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC.
  • HY-120279A
    CFI-400437
    		Inhibitor
    CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM).
  • HY-146792
    PLK1-IN-4
    		Inhibitor
    PLK1-IN-4 is a potent and selective PLK1 inhibitor with IC50 < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma.
  • HY-139652
    PLK1-IN-2
    		Inhibitor
    PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
  • HY-RS10714
    PLK2 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS10716
    Plk2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-RS10717
    PLK3 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-15160C
    TAK-960 monohydrochloride
    		Inhibitor
    TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
  • HY-161046
    PLK1-IN-8
    		Inhibitor
    PLK1-IN-8 (compound TE6) is a PLK1 inhibitor, and inhibits cell proliferation by blocking the cell cycle at G2 phase. PLK1-IN-8 shows anticancer activity in vivo.
  • HY-RS10711
    PLK1 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK1 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-156336
    PLK1-IN-7
    		Inhibitor
    PLK1-IN-7 (compound 30e) is a potent PLK1 inhibitor, with an IC50 of 0.66 nM. PLK1-IN-7 exhibits antiproliferative and antitumor activities.
  • HY-RS10719
    Plk3 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-12135
    Poloxipan
    		Inhibitor
    Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research.
  • HY-129265
    Poloxin-2
    		Inhibitor
    Poloxin-2 is a small molecule Plk1 PBD inhibitor that can effectively induce cell mitotic arrest with an EC50 of approximately 15 μM in HeLa cells. Poloxin-2HT was developed by conjugating a hydrophobic tag (HT) to Poloxin-2, a new application of inhibitors targeting protein-protein interactions. Poloxin-2HT significantly enhanced the effects on cell viability and apoptosis by selectively degrading Plk1 protein, and its effect was stronger than that of untagged Poloxin-2. These data validate hydrophobic tags as a new strategy for targeting and disrupting disease-associated proteins.
  • HY-W276819
    PLK1-IN-9
    		Inhibitor
    PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC50s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model.
  • HY-160624
    CD 10899
    		Inhibitor
    CD 10899 is a hydroxylated metabolite of Volasertib (HY-12137). CD 10899 is pharmacologically active against Polo-like kinase 1 (PLK1) (IC50: 6 nM). Volasertib is an orally active, highly potent and ATP-competitive PLK1 inhibitor. CD 10899 can be used for research of cancer.